Topical Review| Volume 50, ISSUE 4, P297-302, April 2014

Download started.


Mechanism-Based Treatments in Neurodevelopmental Disorders: Fragile X Syndrome

  • Elizabeth Berry-Kravis
    Communications should be addressed to: Dr. Berry-Kravis; Rush University Medical Center; 1725 West Harrison Street, Suite 718; Chicago, IL 60612.
    Department of Pediatrics, Rush University Medical Center, Chicago, Illinois

    Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois

    Department of Biochemistry, Rush University Medical Center, Chicago, Illinois
    Search for articles by this author



      Fragile X syndrome (FXS) is the most common identifiable genetic cause of intellectual disability and autistic spectrum disorders. Recent major advances have been made in the understanding of the neurobiology and functions of fragile X mental retardation protein, the FMR1 gene product, which is absent or reduced in FXS, largely based on work in the fmr1 knockout mouse model. FXS has emerged as a disorder of synaptic plasticity associated with abnormalities of long-term depression and long-term potentiation and immature dendritic spine architecture, related to dysregulation of dendritic translation typically activated by group I mGluR and other receptors. This work has led to efforts to develop treatments for FXS with neuroactive molecules targeted to pathways dysregulated in the absence of fragile X mental retardation protein.


      These agents have been shown to rescue molecular, spine, and behavioral phenotypes in the FXS mouse model, and clinical trials are underway to translate findings in animal models of FXS to humans, raising complex issues about trial design and outcome measures to assess disease-modifying changes that might be associated with treatment. Genes known to be causes of autistic spectrum disorders interact with the translational pathway defective in FXS and it is likely that there will be substantial overlap in molecular pathways and mechanisms of synaptic dysfunction. Thus targeted treatment and clinical trial strategies in FXS may serve as a model for ASD and other cognitive disorders.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Pediatric Neurology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Coffee B.
        • Keith K.
        • Albizua I.
        • et al.
        Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA.
        Am J Hum Genet. 2009; 85: 503-514
        • Willemsen R.
        • Levenga J.
        • Oostra B.A.
        CGG repeat in the FMR1 gene: size matters.
        Clin Genet. 2011; 80: 214-225
        • Seltzer M.M.
        • Baker M.W.
        • Hong J.
        • Maenner M.
        • Greenberg J.
        • Mandel D.
        Prevalence of CGG expansions of the FMR1 gene in a US population-based sample.
        Am J Med Genet B Neuropsychiatr Genet. 2012; 159B: 589-597
        • Tassone F.
        • Iong K.P.
        • Tong T.
        • et al.
        FMR1 CGG allele size and expansion prevalence ascertained through newborn screening in the United States.
        Genome Med. 2012; 4: 100
        • Hagerman R.J.
        • Berry-Kravis E.
        • Kaufmann W.E.
        • et al.
        Advances in the treatment of fragile X syndrome.
        J Pediatr. 2009; 123: 378-390
        • Berry-Kravis E.
        • Sumis A.
        • Hervey C.
        • Mathur S.
        Clinic-based retrospective analysis of psychopharmacology for behavior in fragile X syndrome.
        Int J Pediatr. 2012; 2012: 843016
        • Wang L.W.
        • Berry-Kravis E.
        • Hagerman R.J.
        Fragile X: leading the way for targeted treatments in autism.
        Neurotherapeutics. 2010; 7: 264-274
        • Berry-Kravis E.
        • Raspa M.
        • Loggin-Hester L.
        • Bishop E.
        • Holiday D.
        • Bailey D.
        Seizures in fragile X syndrome: characteristics and co-morbid diagnoses.
        Am J Intellect Dev Disabil. 2010; 115: 461-472
        • Loesch D.Z.
        • Huggins R.M.
        • Hagerman R.J.
        Phenotypic variation and FMRP levels in fragile X.
        Ment Retard Dev Disabil Res Rev. 2004; 10: 31-41
        • Bailey Jr., D.B.
        • Raspa M.
        • Bishop E.
        • Olmsted M.
        • Malya U.
        • Berry-Kravis E.
        Medication utilization for targeted symptoms in children and adults with fragile X syndrome: U.S. survey.
        J Dev Behav Pediatr. 2012; 33: 62-69
        • The Dutch-Belgian Fragile X Consortium
        Fmr1 knockout mice: a model to study fragile X mental retardation.
        Cell. 1994; 78: 23-33
        • Grossman A.W.
        • Aldridge G.M.
        • Weiler I.J.
        • Greenough W.T.
        Local protein synthesis and spine morphogenesis: fragile X syndrome and beyond.
        J Neurosci. 2006; 26: 7151-7155
        • Huber K.M.
        • Gallagher S.M.
        • Warren S.T.
        • Bear M.F.
        Altered synaptic plasticity in a mouse model of fragile X mental retardation.
        Proc Natl Acad Sci USA. 2002; 99: 7746-7750
        • Berry-Kravis E.
        • Knox A.
        • Hervey C.
        Targeted treatments for fragile X syndrome.
        J Neurodev Disord. 2011; 3: 193-210
        • Bagni C.
        • Tassone F.
        • Neri G.
        • Hagerman R.
        Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics.
        J Clin Invest. 2012; 122: 4314-4322
        • Bear M.F.
        • Huber K.M.
        • Warren S.T.
        The mGluR theory of fragile X mental retardation.
        Trends Neurosci. 2004; 27: 370-377
        • Yan Q.J.
        • Rammal M.
        • Tranfaglia M.
        • Bauchwitz R.P.
        Suppression of two major Fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP.
        Neuropharmacology. 2005; 49: 1053-1066
        • de Vrij F.M.
        • Levenga J.
        • van der Linde H.C.
        • et al.
        Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice.
        Neurobiol Dis. 2008; 31: 127-132
        • Dolen G.
        • Osterweil E.
        • Shankaranarayana Rao B.S.
        • et al.
        Correction of fragile X syndrome in mice.
        Neuron. 2007; 56: 955-962
        • McBride S.M.
        • Choi C.H.
        • Wang Y.
        • et al.
        Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a model of fragile X syndrome.
        Neuron. 2005; 45: 753-764
        • Michalon A.
        • Sidorov M.
        • Ballard T.M.
        • et al.
        Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.
        Neuron. 2012; 74: 49-56
        • Yuskaitis C.J.
        • Mines M.A.
        • King M.K.
        • Sweatt J.D.
        • Miller C.A.
        • Jope R.S.
        Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome.
        Biochem Pharmacol. 2010; 79: 632-646
        • Berry-Kravis E.
        • Sumis A.
        • Hervey C.
        • et al.
        Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome.
        J Dev Behav Pediatr. 2008; 29: 293-302
        • Bilousova T.V.
        • Dansie L.
        • Ngo M.
        • et al.
        Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model.
        J Med Genet. 2009; 46: 94-102
        • Paribello C.
        • Tao L.
        • Folino A.
        • et al.
        Open-label add-on treatment trial of minocycline in fragile X syndrome.
        BMC Neurol. 2010; 10: 91
        • Leigh M.J.
        • Nguyen D.V.
        • Mu Y.
        • et al.
        A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome.
        J Dev Behav Pediatr. 2013; 34: 147-155
        • Chang S.
        • Bray S.M.
        • Li Z.
        • et al.
        Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila.
        Nat Chem Biol. 2008; 4: 256-263
        • Pacey L.K.
        • Heximer S.P.
        • Hampson D.R.
        Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures.
        Mol Pharmacol. 2009; 76: 18-24
        • Henderson C.
        • Wijetunge L.
        • Kinoshita M.N.
        • et al.
        Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABA(B) receptors with arbaclofen.
        Sci Transl Med. 2012; 4: 152ra128
        • Berry-Kravis E.
        • Hessl D.
        • Rathmell B.
        • et al.
        Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial.
        Sci Transl Med. 2012; 4: 152ra127
        • Maltas S.
        • Widaman K.F.
        • Hall S.
        • et al.
        Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment.
        J Autism Dev Disord. 2012; 42: 1377-1392
        • Erickson C.A.
        • Wink L.K.
        • Ray B.
        • et al.
        Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome.
        Psychopharmacology (Berl). 2013; 228: 75-84
        • Berry-Kravis E.
        • Hessl D.
        • Coffey S.
        • et al.
        A pilot open label, single dose trial of fenobam in adults with fragile X syndrome.
        J Med Genet. 2009; 46: 266-271
        • Jacquemont S.
        • Curie A.
        • des Portes V.
        • et al.
        Epigenetic modification of the FMR1 gene in fragile X patients leads to a differential response to the mGluR5antagonist AFQ056.
        Sci Trans Med. 2011; 3: 64ra1
        • Berry-Kravis E
        • Hessl D
        • Abbeduto L
        • et al.
        Outcome measures for fragile X syndrome clinical trials: Consensus Statement from the NIH Fragile X Coordinating Group.
        J Dev Behav Pediatr. 2013; 34: 508-522
        • Farzin F.
        • Scaggs F.
        • Hervey C.
        • Berry-Kravis E.
        • Hessl D.
        Reliability of eye tracking and pupillometry measures in individuals with fragile X syndrome.
        J Autism Dev Disord. 2011; 41: 1515-1522
        • Iossifov I.
        • Ronemus M.
        • Levy D.
        • et al.
        De novo gene disruptions in children on the autistic spectrum.
        Neuron. 2012; 74: 285-299

      Linked Article

      • Mechanism-Based Treatment in Tuberous Sclerosis Complex
        Pediatric NeurologyVol. 50Issue 4
        • Preview
          Tuberous sclerosis complex (TSC) is a genetic multisystem disorder that affects the brain in almost every patient. It is caused by a mutation in the TSC1 or TSC2 genes, which regulate mammalian target of rapamycin (mTOR), a key player in control of cellular growth and protein synthesis. The most frequent neurological symptoms are seizures, which occur in up to 90% of patients and often are intractable, followed by autism spectrum disorders, intellectual disability, attention deficit-hyperactivity disorder, and sleep problems.
        • Full-Text
        • PDF